Vivos Therapeutics, Inc. (VVOS) Key Metrics
VVOS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.4M
- Enterprise value
- $14.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.2
- Price / book
- 6.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 6.07
VVOS key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsVVOS returns How much profit the business earns on the capital it uses.
VVOS financial health Debt, liquidity and how easily interest is covered.
VVOS efficiency & capital use Working capital cycle and where the cash goes.
VVOS valuation history
VVOS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VVOS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VVOS cash returned to shareholders
VVOS price vs earnings per share
VVOS key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $20.9M | — | — | — | — | — | — | — |
| Enterprise value | $32.3M | — | — | — | — | — | — | — |
| Price / sales | 1.2 | — | — | — | — | — | — | — |
| EV / sales | 1.9 | — | — | — | — | — | — | — |
| Earnings yield | −101.8% | — | — | — | — | — | — | — |
| Free cash flow yield | −84.4% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.03 | $4.29 | $12.44 | $10.05 | $56.25 | $147.75 | — | — |
| Per share | ||||||||
| Revenue per share | $1.70 | — | — | — | — | — | — | — |
| Earnings per share | −$2.07 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.49 | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.71 | — | — | — | — | — | — | — |
| Cash per share | $0.20 | — | — | — | — | — | — | — |
| Book value per share | −$0.15 | — | — | — | — | — | — | — |
| Tangible book value per share | −$1.37 | — | — | — | — | — | — | — |
| Capex per share | $0.23 | — | — | — | — | — | — | — |
| Debt per share | $1.31 | — | — | — | — | — | — | — |
| Shares outstanding | 10.3M | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | — | −266.3% | −521.2% | −157.2% | −95.6% | −172.6% | — | −174.8% |
| Return on invested capital (ROIC) | −238.3% | −444.7% | −613.0% | −578.5% | −978.9% | — | −366.8% | −154.6% |
| Return on assets (ROA) | −105.0% | −85.6% | −111.1% | −100.6% | −68.8% | −73.3% | −136.5% | −102.9% |
| Return on tangible assets | −169.4% | −92.3% | −181.9% | −225.5% | −66.5% | −53.9% | −256.6% | −254.2% |
| Free cash flow margin | −100.9% | −88.2% | −92.4% | −128.0% | −107.4% | −44.4% | −48.4% | −173.1% |
| Financial health | ||||||||
| Total debt | $13.5M | $1.5M | $2.0M | $2.4M | $1.6M | $1.3M | $3.7M | $686,545 |
| Cash & short-term investments | $2.0M | $6.3M | $1.6M | $3.5M | $24.0M | $18.2M | $469,353 | $1.3M |
| Net debt | $11.5M | −$4.7M | $352,000 | −$1.1M | −$22.4M | −$16.9M | $3.2M | −$568,178 |
| Debt / equity | — | 0.19 | 4.85 | 0.50 | 0.06 | 0.08 | — | 0.14 |
| Debt / assets | 0.54 | 0.10 | 0.19 | 0.18 | 0.05 | 0.05 | 0.49 | 0.08 |
| Current ratio | 0.24 | 1.50 | 0.34 | 0.80 | 3.64 | 2.61 | 0.22 | 0.93 |
| Quick ratio | 0.24 | 1.50 | 0.34 | 0.80 | 3.71 | 2.61 | 0.19 | 0.93 |
| Interest coverage | — | — | — | -21.1 | — | -124.5 | -76.7 | -81.0 |
| Working capital | −$13.7M | $2.5M | −$4.8M | −$1.4M | $19.8M | $12.6M | −$7.1M | −$145,561 |
| Invested capital | $10.0M | $3.2M | $763,000 | $3.7M | $3.1M | $1,758 | $297,123 | $4.3M |
| Tangible asset value | −$14.2M | $4.7M | −$2.9M | $1.7M | $22.4M | $14.0M | −$6.3M | −$57,004 |
| Net current asset value | −$22.3M | $143,000 | −$7.9M | −$3.5M | $19.2M | $12.0M | −$8.5M | −$1.4M |
| Graham net-net per share | −$2.29 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | — | — | $3.7M | $3.8M | — |
| Share buybacks (net) | — | — | — | $0 | $1.5M | $2.1M | $350,000 | $1.0M |
| Capex / revenue | 13.4% | 3.8% | 5.8% | 5.8% | 14.2% | 0.9% | 1.5% | 33.0% |
| Capex / depreciation | 1.79 | 0.98 | 1.29 | 1.38 | 3.27 | 0.17 | 0.23 | 2.05 |
| Stock-based compensation / revenue | 3.8% | 5.1% | 6.7% | 15.0% | 15.7% | 16.6% | 17.4% | 33.8% |
| R&D / revenue | — | 0.7% | 0.7% | 1.2% | — | — | — | — |
| SG&A / revenue | 167.0% | 130.5% | 180.8% | 214.6% | 185.6% | 140.9% | 162.2% | 275.2% |
| Efficiency | ||||||||
| Days sales outstanding | 21.0 | 7.7 | 8.7 | 24.8 | 35.0 | 34.5 | 24.8 | 57.3 |
| Days of inventory on hand | — | — | 0.0 | — | -22.0 | 18.1 | 17.6 | 0.0 |
| Days payables outstanding | 73.4 | 98.4 | 117.4 | 70.8 | 72.5 | 128.3 | 103.9 | 160.0 |
| Cash conversion cycle (days) | -52.4 | -90.8 | -108.6 | -46.1 | -59.6 | -75.6 | -61.4 | -102.7 |
| Receivables turnover | 17.35 | 47.57 | 41.88 | 14.73 | 10.44 | 10.57 | 14.69 | 6.37 |
| Payables turnover | 4.97 | 3.71 | 3.11 | 5.15 | 5.03 | 2.85 | 3.51 | 2.28 |
| Inventory turnover | — | — | 5,530,000.00 | — | — | 20.11 | 20.74 | 1,081,641.00 |
| Asset turnover | 0.86 | 1.16 | 1.13 | 0.68 | 0.57 | 0.79 | 1.45 | 0.46 |
| Average receivables | $1.0M | $316,000 | $329,500 | $1.1M | $1.6M | $1.2M | $775,586 | $595,187 |
| Average payables | $1.4M | $1.6M | $1.8M | $1.2M | $850,500 | $932,211 | $778,752 | $474,083 |
| Average inventory | — | — | $1 | — | −$258,000 | $131,908 | $131,908 | $1 |
| Intangibles / total assets | 50.2% | 21.0% | 30.4% | 22.9% | 9.5% | 11.6% | 44.5% | 59.5% |
Computed from VVOS's annual financial statements (latest annual report filed April 15, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VVOS valuation and financial ratios
Vivos Therapeutics earned a return on invested capital of −238.3% in fiscal 2025. It ended the year with $13.5 million of debt and $2.0 million in cash and short-term investments, net debt of $11.5 million.
See the VVOS income statement, the VVOS chart for price history, or the VVOS stock overview for the latest quote and news.
VVOS key metrics FAQ
What is Vivos Therapeutics's ROIC?
Vivos Therapeutics's return on invested capital was −238.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Vivos Therapeutics have?
Vivos Therapeutics had total debt of $13.5 million at the end of fiscal 2025.
What is Vivos Therapeutics's free cash flow yield?
Vivos Therapeutics generated -$17.6 million of free cash flow in fiscal 2025, a free cash flow yield of −84.4% on its market value at year-end ($20.9 million).
What is Vivos Therapeutics's current ratio?
Vivos Therapeutics's current ratio was 0.24 at the end of fiscal 2025: current assets were 0.24 times current liabilities.